Accrufer is owned by Shield Tx.
Accrufer contains Ferric Maltol.
Accrufer has a total of 3 drug patents out of which 0 drug patents have expired.
Accrufer was authorised for market use on 25 July, 2019.
Accrufer is available in capsule;oral dosage forms.
Accrufer can be used as method of treating iron deficiency.
Drug patent challenges can be filed against Accrufer from 2023-07-26.
The generics of Accrufer are possible to be released after 23 October, 2035.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US9802973||SHIELD TX||Crystalline forms of ferric maltol|| |
(12 years from now)
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US9248148||SHIELD TX||Mono (iron hydroxypyrone) and combination (iron hydroxypyrone and GI inflammation inhibiting agents) compositions for anaemia or H. pylori infections|| |
(8 years from now)
|US10179120||SHIELD TX||Dosage regimen of ferric trimaltol|| |
(11 years from now)
|New Chemical Entity Exclusivity (NCE)||Jul 25, 2024|
Drugs and Companies using FERRIC MALTOL ingredient
NCE-1 date: 2023-07-26
Market Authorisation Date: 25 July, 2019
Treatment: Method of treating iron deficiency
Korea, Republic of
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic